Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Unmet Needs And Thinking Big,' Inari Buys LimFlow For $250m To Add CLTI Treatment

Executive Summary

LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.

You may also be interested in...



Cardiovascular Catch-Up: Philips New AI Finds AF Needle In ECG Haystack; LimFlow Moves Closer To US Approval

Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small. Part two of this month's installment includes updates from lesser-known companies that you might have missed, including Cardiologs, Rhythm Management, LimFlow and ShockWave.

R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial

An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

LimFlow On Target For 2021 US Launch Of Deep Vein Arterialization System

The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel